Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen is a Danish business executive who has served as the president and chief executive officer of the global healthcare company Novo Nordisk since 2017. He succeeded the long-serving Lars Rebien Sørensen and has overseen a period of transformative growth for the pharmaceutical giant, driven largely by the success of its GLP-1-based therapies for diabetes and obesity. Under his leadership, Novo Nordisk has become one of the most valuable companies in Europe, significantly expanding its global footprint and research initiatives.

Early life and education

Lars Fruergaard Jørgensen was born in Denmark in 1966. He pursued his higher education at Aarhus University, where he earned a master's degree in economics and business administration. He furthered his academic credentials with a graduate diploma in business administration (HD) from the University of Southern Denmark. His early professional development included a significant period at the international consultancy McKinsey & Company, where he worked as a management consultant, gaining extensive experience in corporate strategy and operations within the healthcare industry.

Career at Novo Nordisk

Jørgensen joined Novo Nordisk in 1991, beginning a long tenure that would see him hold numerous senior positions across the organization. His early roles included various positions within finance and corporate development. He later served as the senior vice president of corporate development, where he was instrumental in shaping the company's strategic portfolio. A pivotal step in his career was his appointment as the head of Novo Nordisk's operations in Japan, a key growth market, where he gained crucial international management experience. Upon returning to the company's headquarters in Bagsværd, he assumed the role of senior vice president and head of Novo Nordisk's Diabetes Finished Products unit, directly overseeing a core business segment.

Leadership and strategic direction

Appointed president and chief executive officer in 2017, Jørgensen took the helm of Novo Nordisk during a critical period. His strategic direction has been characterized by a sharp focus on expanding the company's leadership in diabetes care and establishing a dominant position in the burgeoning obesity treatment market. This was realized through the blockbuster success of drugs like semaglutide, marketed as Ozempic and Wegovy. Under his guidance, Novo Nordisk has made substantial investments in research and development, forging partnerships with biotech firms and academic institutions like the University of Oxford. He has also prioritized expanding manufacturing capacity globally, including major investments in Kalundborg and Chartres, to meet unprecedented demand. His tenure has seen Novo Nordisk ascend to become the most valuable listed company in Europe by market capitalization, significantly impacting the Copenhagen Stock Exchange and the broader economy of Denmark.

Recognition and awards

For his leadership and the company's performance, Jørgensen has received significant recognition. Under his stewardship, Novo Nordisk has consistently been ranked highly on the Access to Medicine Index and recognized for its sustainability efforts. He was named the world's best-performing chief executive in 2023 by the Harvard Business Review in its annual ranking of CEOs. The dramatic rise in the company's valuation under his leadership has been widely noted in financial publications such as the Financial Times and Bloomberg.

Personal life

Lars Fruergaard Jørgensen maintains a relatively private personal life. He is married and has children. Known for a calm and analytical demeanor, he is an avid runner and has participated in several marathon events, including the Berlin Marathon. He resides with his family in the greater Copenhagen area.

Category:1966 births Category:Living people Category:Danish businesspeople Category:Novo Nordisk people Category:Chief executives in the pharmaceutical industry Category:Aarhus University alumni Category:University of Southern Denmark alumni